A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria.


Journal

Future microbiology
ISSN: 1746-0921
Titre abrégé: Future Microbiol
Pays: England
ID NLM: 101278120

Informations de publication

Date de publication:
04 2022
Historique:
pubmed: 15 3 2022
medline: 5 4 2022
entrez: 14 3 2022
Statut: ppublish

Résumé

Bacterial pneumonia is an infection of the lung caused by bacteria that is potentially deadly, costly, and affects millions of people worldwide every year. Treatment is becoming more challenging-many current treatments no longer work well because some strains of bacteria that cause pneumonia have become resistant to current antibiotics. Many of the antibiotics that do still work have undesirable side effects. Therefore, new antibiotics that work differently are needed to treat bacterial pneumonia. Lefamulin (brand name, Xenleta After the studies were completed, the researchers looked back at what kinds of bacteria were identified from the study participants. Lefamulin worked well to kill bacteria and to improve CABP symptoms for most kinds of infecting bacteria, including bacteria resistant to many current antibiotics. These results suggest that lefamulin, by itself, provides a much-needed treatment option for CABP that covers most of the key bacteria causing this infection.

Identifiants

pubmed: 35285291
doi: 10.2217/fmb-2021-0276
pmc: PMC9096602
doi:

Substances chimiques

Anti-Bacterial Agents 0
Diterpenes 0
Polycyclic Compounds 0
Thioglycolates 0
lefamulin 21904A5386

Types de publication

Journal Article Review Research Support, U.S. Gov't, P.H.S. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

397-410

Commentaires et corrections

Type : CommentOn
Type : CommentOn

Auteurs

Susanne Paukner (S)

Nabriva Therapeutics GmbH, Vienna, Austria.

Gregory J Moran (GJ)

Department of Emergency Medicine & Division of Infectious Diseases, Olive View-UCLA Medical Center, Los Angeles, CA, USA.

Christian Sandrock (C)

Department of Internal Medicine, UC Davis School of Medicine, Sacramento, CA, USA.

Thomas M File (TM)

Infectious Disease Division, Summa Health, Akron, OH, USA.

Jorge E Vidal (JE)

Department of Microbiology & Immunology, University of Mississippi Medical Center, Jackson, MS, USA.

Ken B Waites (KB)

Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.

Steven P Gelone (SP)

Nabriva Therapeutics US, Inc., Fort Washington, PA, USA.

Kalvin Yu (K)

Becton, Dickinson & Company, Franklin Lakes, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH